Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Auderghem – page 53

1 992 clinical trials in Auderghem, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Auderghem at a glance
1 992
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 992 trials in Auderghem

Open in trial search

Dermatomyositis+1

Recruiting

Study on the Effectiveness of Dazukibart in Adults with Active Dermatomyositis or Polymyositis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Azathioprine
  • Sponsor:Pfizer Inc.

Long-term Safety Study of Ciltacabtagene Autoleucel for Patients with Multiple Myeloma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ciltacabtagene Autoleucel
  • Sponsor:Janssen Cilag International

Study on Monitoring vs. Rivaroxaban for Patients with Low-Risk Isolated Subsegmental Pulmonary Embolism

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Rivaroxaban
  • Sponsor:Insel Gruppe AG

Study on Treating Acute Myeloid Leukemia in Children and Adolescents Using Gemtuzumab Ozogamicin and a Drug Combination

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Cytarabine
  • Sponsor:Prinses Maxima Centrum voor Kinderoncologie B.V.

Study on Long-Term Safety and Effects of DNL310 for Patients with Mucopolysaccharidosis Type II (MPS II)

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Tividenofusp alfa
  • Sponsor:Denali Therapeutics Inc.

Study on Conditioning Treatments with Busulfan, Clofarabine, and Fludarabine for Children with Acute Myeloid Leukemia Undergoing Stem Cell Transplantation

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Busulfan
  • Sponsor:Vastra Gotalandsregionen

Study on Elacestrant for Treating ER+/HER2- Breast Cancer in Patients with ctDNA Relapse

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Study on Lutetium (177Lu) Vipivotide Tetraxetan to Delay Recurrence in Adult Men with PSMA-Positive Oligometastatic Prostate Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Gozetotide
  • Sponsor:Novartis Pharma AG

Study on Personalized Antithrombotic Therapy with Acenocoumarol, Phenprocoumon, and Apixaban for Patients with Aortic Valve Stenosis Post-TAVI

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Acenocoumarol
  • Sponsor:St. Antonius Ziekenhuis

Long-term Follow-up Study for Patients with Solid and Blood Cancers Treated with Brexucabtagene Autoleucel or Axicabtagene Ciloleucel

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:KITE-363
  • Sponsor:Kite Pharma Inc.

Study on Upadacitinib and Tocilizumab for Children and Teens with Active Systemic Juvenile Idiopathic Arthritis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Tocilizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on Lowering INR to Reduce Bleeding in Patients with Mechanical Aortic Valves Using Warfarin, Acenocoumarol, and Phenprocoumon

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Acenocoumarol
  • Sponsor:Hamilton Health Sciences Corporation

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Auderghem

What the registry says about research in the country

01 Neoplasms

In Auderghem, researchers are concentrating on lung cancer, specifically Non‑Small Cell Lung Cancer and small cell lung cancer. The two active studies compare new immune‑targeted agents such as pumitamig and obrixtamig against established therapies like pembrolizumab and standard chemotherapy, aiming to improve overall survival and disease control.

  • Comparative efficacy of novel immunotherapies
  • Evaluation of survival benefit in advanced disease
  • Biomarker‑guided patient selection (e.g., DLL3 expression)
  • Combination regimens with checkpoint inhibitors

Both trials are actively recruiting, reflecting a growing commitment in Auderghem to advance treatment options for patients with aggressive lung cancers.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.